This site is intended for healthcare professionals
EMC Drug Feed
Drug information

OTC
Read time: 2 mins
Last updated: 14 Jul 2017

Summary of product characteristics


1. Name of the medicinal product

Strepsils Extra Citrus Menthol Lozenges

Strepsils Extra Strength Lemon Menthol Lozenges

Strepsils Sore Throat Pain Relief Honey & Lemon Flavour 2.4mg Lozenges


2. Qualitative and quantitative composition

Hexylresorcinol Ph Eur 2.4mg

For excipients, see 6.1


3. Pharmaceutical form

Lozenge


4.1. Therapeutic indications

As an antiseptic and local anaesthetic for the relief of sore throat and its associated pain.


4.2. Posology and method of administration

For oral administration

Adults, the elderly and children 6 years and over: One lozenge dissolved slowly in the mouth every three hours or as required.

Do not take more than 12 lozenges in 24 hours.

Not to be given to children under 6 years.


4.3. Contraindications

Hypersensitivity to any of the ingredients.


4.4. Special warnings and precautions for use

The label will convey:

Do not exceed the stated dose.

Keep out of the reach of children.

Not to be given to children under 6 years.

This product is unsuitable hereditary fructose intolerance, glucose-galactose malabsorption syndrome, or sucrose-isomaltase deficiency.


4.5. Interaction with other medicinal products and other forms of interaction

None known.


4.6. Fertility, pregnancy and lactation

There is a lack of evidence of safety of the product in human pregnancy, but hexylresorcinol has been used widely in lozenges for many years without apparent ill consequence. However as with all medicines, caution should be exercised during pregnancy and lactation.


4.7. Effects on ability to drive and use machines

No adverse effects known.


4.8. Undesirable effects

None known.

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.


4.9. Overdose

Hexylresorcinol overdosage may cause minor gastrointestinal irritation. Treatment would be withdrawal of the product and symptomatic measures as appropriate.


5.1. Pharmacodynamic properties

Hexylresorcinol is a local anaesthetic for topical use on the mucous membranes of the mouth and throat. Mild antiseptic activity has also been demonstrated.

The product base has a demulcent action.


5.2. Pharmacokinetic properties

Pharmacokinetic considerations do not arise since the pharmacological action is local to the oropharyngeal cavity.


5.3. Preclinical safety data

There are no pre-clinical data available specific to the product.


6.1. List of excipients

Liquid Sucrose, Liquid Glucose, Propylene Glycol, Honey and Lemon Flavour.


6.2. Incompatibilities

Not applicable


6.3. Shelf life

24 months


6.4. Special precautions for storage

Do not store above 25°C. Store in the original packaging. Keep in the outer carton.


6.5. Nature and contents of container

Blister packs of 250 micron PVC coated 90 gsm PVDC with 20 micron hard temper aluminium foil, heat sealed to the PVC/PVDC blister containing 6, 8, 10, 12, 16, 20, 24, 32 or 36 lozenges in a carton.


6.6. Special precautions for disposal and other handling

None specific to the product/ pack


7. Marketing authorisation holder

Reckitt Benckiser Healthcare (UK) Ltd

Slough

SL1 3UH


8. Marketing authorisation number(s)

PL 00063/0394


9. Date of first authorisation/renewal of the authorisation

06/04/2010


10. Date of revision of the text

27/06/2017

4.1 Therapeutic indications

As an antiseptic and local anaesthetic for the relief of sore throat and its associated pain.

4.2 Posology and method of administration

For oral administration

Adults, the elderly and children 6 years and over: One lozenge dissolved slowly in the mouth every three hours or as required.

Do not take more than 12 lozenges in 24 hours.

Not to be given to children under 6 years.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

The label will convey:

Do not exceed the stated dose.

Keep out of the reach of children.

Not to be given to children under 6 years.

This product is unsuitable hereditary fructose intolerance, glucose-galactose malabsorption syndrome, or sucrose-isomaltase deficiency.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

There is a lack of evidence of safety of the product in human pregnancy, but hexylresorcinol has been used widely in lozenges for many years without apparent ill consequence. However as with all medicines, caution should be exercised during pregnancy and lactation.

4.7 Effects on ability to drive and use machines

No adverse effects known.

4.8 Undesirable effects

None known.

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).